Neutralizing antibody response to SARS-CoV-2 variants, as determined by the MSD multiplex assay, following COVID-19 vaccination in cancer patients by Christopher W. Dukes, Junmin Whiting, Qianxing Mo, Christopher L. Cubitt, Barbara J. Kuter, Brett Leav, Kayoko Kennedy, Julie Rathwell, Shari Pilon-Thomas, Anna R. Giuliano

Get full text

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML by David A. Sallman, Rami S. Komrokji, Amy E. Dezern, Marie Sebert, Guillermo Garcia‐Manero, Ramy Rahmé, Eric S. Winer, Jacqueline Lehmann‐Che, Gail J. Roboz, Isabelle Madelaine, Mikkael A. Sekeres, Pierre Peterlin, Onyee Chan, Odile Beyne‐Rauzy, Andrew Kuykendall, Christian Recher, Amy McLemore, Aspasia Stamatoullas, Ling Zhang, Lise Willems, Qianxing Mo, Emmanuel Raffoux, Lisa Nardelli, Céline Berthon, Najla H. Al Ali, Bruno Quesnel, Eric Padron, Hagop M. Kantarjian, Alan F. List, Lionel Ades, Jeffrey E. Lancet, Pierre Fenaux, Thomas Cluzeau

Get full text